This paper is in the following e-collection/theme issue:

Non-randomized Protocols and Methods (ehealth) (568)

Published on in Vol 5, No 4 (2016): Oct-Dec

Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation Into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo)

Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation Into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo)

Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation Into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo)

Authors of this article:

Alanna McEneny-King1 Author Orcid Image ;   Gary Foster2, 3 Author Orcid Image ;   Alfonso Iorio4, 5 Author Orcid Image ;   Andrea N Edginton1 Author Orcid Image
Article Authors Cited by (42) Tweetations (1) Metrics

Journals

  1. Escobar M, Santagostino E, Mancuso M, Coppens M, Balasa V, Taylor J, Iorio A, Negrier C. Switching patients in the age of long-acting recombinant products?. Expert Review of Hematology 2019;12(sup1):1 View
  2. Santoro C, Fuh B, Le P, Maes P, Berrueco R, Mingot‐Castellano E, von Mackensen S, Solms A, Wang M. BAY 81‐8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study. European Journal of Haematology 2020;105(2):164 View
  3. McEneny-King A, Chelle P, Henrard S, Hermans C, Iorio A, Edginton A. Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis. Pharmaceutics 2017;9(4):47 View
  4. Zhou J, Barnes R, Foster G, Iorio A, Cramer T, von Drygalski A. Joint Bleeding Tendencies in Adult Patients With Hemophilia: It’s Not All Pharmacokinetics. Clinical and Applied Thrombosis/Hemostasis 2019;25 View
  5. Iorio A, Iserman E, Blanchette V, Dolan G, Escuriola Ettingshausen C, Hermans C, Negrier C, Oldenburg J, Reininger A, Rodriguez‐Merchan C, Spannagl M, Valentino L, Young G, Steinitz‐Trost K, Gringeri A. Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement. Haemophilia 2017;23(3) View
  6. Chowdary P. Extended half-life recombinant products in haemophilia clinical practice – Expectations, opportunities and challenges. Thrombosis Research 2020;196:609 View
  7. Chelle P, Yeung C, Bonanad S, Morales Muñoz J, Ozelo M, Megías Vericat J, Iorio A, Spears J, Mir R, Edginton A. Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients. Journal of Pharmacokinetics and Pharmacodynamics 2019;46(5):427 View
  8. Hecht M, Veigure R, Couchman L, S Barker C, Standing J, Takkis K, Evard H, Johnston A, Herodes K, Leito I, Kipper K. Utilization of Data Below the Analytical Limit of Quantitation in Pharmacokinetic Analysis and Modeling: Promoting Interdisciplinary Debate. Bioanalysis 2018;10(15):1229 View
  9. Lissitchkov T, Klukowska A, Pasi J, Kessler C, Klamroth R, Liesner R, Belyanskaya L, Walter O, Knaub S, Bichler J, Jansen M, Oldenburg J. Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program. Therapeutic Advances in Hematology 2019;10 View
  10. Iorio A, Fischer K, Blanchette V, Rangarajan S, Young G, Morfini M. Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates. Thrombosis and Haemostasis 2017;117(06):1023 View
  11. Iorio A, McEneny-King A, Keepanasseril A, Foster G, Edginton A. What is the Role for Population Pharmacokinetics in Hemophilia?. International Journal of Pharmacokinetics 2017;2(2):125 View
  12. McEneny-King A, Chelle P, Iorio A, Edginton A. The effect of unmeasurable endogenous plasma factor activity levels on factor VIII dosing in patients with severe hemophilia A. Thrombosis Research 2018;170:53 View
  13. McEneny‐King A, Yeung C, Edginton A, Iorio A, Croteau S. Clinical application of Web Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS‐Hemo): Patterns of blood sampling and patient characteristics among clinician users. Haemophilia 2020;26(1):56 View
  14. Klukowska A, Komrska V, Vdovin V, Zozulya N, Lissitchkov T, Oldenburg J, Ettingshausen C. octanate®: over 20 years of clinical experience in overcoming challenges in haemophilia A treatment. Therapeutic Advances in Hematology 2020;11 View
  15. Dargaud Y, Delavenne X, Hart D, Meunier S, Mismetti P. Individualized PK‐based prophylaxis in severe haemophilia. Haemophilia 2018;24(S2):3 View
  16. Solms A, Iorio A, Ahsman M, Vis P, Shah A, Berntorp E, Garmann D. Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach. Clinical Pharmacokinetics 2020;59(5):605 View
  17. Allard Q, Djerada Z, Pouplard C, Repessé Y, Desprez D, Galinat H, Frotscher B, Berger C, Harroche A, Ryman A, Flaujac C, Chamouni P, Guillet B, Volot F, Szymezak J, Nguyen P, Cazaubon Y. Real Life Population Pharmacokinetics Modelling of Eight Factors VIII in Patients with Severe Haemophilia A: Is It Always Relevant to Switch to an Extended Half-Life?. Pharmaceutics 2020;12(4):380 View
  18. Ragni M, Croteau S, Morfini M, Cnossen M, Iorio A. Pharmacokinetics and the transition to extended half‐life factor concentrates: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis 2018;16(7):1437 View
  19. Croteau S, Wheeler A, Khan O, Haley K, Borst A, Lattimore S, Yeung C, Iorio A. Pharmacokinetic‐tailored approach to hemophilia prophylaxis: Medical decision making and outcomes. Research and Practice in Thrombosis and Haemostasis 2020;4(2):326 View
  20. Delavenne X, Dargaud Y, Ollier E, Négrier C. Dose tailoring of human cell line‐derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia A. British Journal of Clinical Pharmacology 2019;85(4):771 View
  21. Berntorp E. If you know you will also see: population pharmacokinetics is the way to personalize and optimize prophylaxis in hemophilia. Journal of Thrombosis and Haemostasis 2017;15(6):1103 View
  22. Carcao M, Chelle P, Clarke E, Kim L, Tiseo L, Morfini M, Hossain T, Rand M, Brown C, Edginton A, Lillicrap D, Iorio A, Blanchette V. Comparative pharmacokinetics of two extended half‐life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?. Journal of Thrombosis and Haemostasis 2019;17(7):1085 View
  23. Hajducek D, Chelle P, Hermans C, Iorio A, McEneny‐King A, Yu J, Edginton A. Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS‐Hemo project. Haemophilia 2020;26(3):384 View
  24. Megías-Vericat J, Bonanad S, Haya S, Cid A, Marqués M, Monte E, Pérez-Alenda S, Bosch P, Querol F, Poveda J. Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A. Thrombosis Research 2019;174:151 View
  25. Berntorp E. Replacement therapy during surgery in von Willebrand disease needs personalization. Haemophilia 2018;24(3):338 View
  26. Iorio A, Blanchette V, Blatny J, Collins P, Fischer K, Neufeld E. Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis 2017;15(12):2461 View
  27. Yu J, Iorio A, Edginton A. A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients. Thrombosis Research 2020;196:550 View
  28. Chen Z, Huang K, Li G, Zhen Y, Wu X, Di A, Liu G, Li Z, Alfonso I, Wu R. Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A. Pediatric Investigation 2021;5(1):38 View
  29. Versloot O, Iserman E, Chelle P, Germini F, Edginton A, Schutgens R, Iorio A, Fischer K. Terminal half‐life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database. Journal of Thrombosis and Haemostasis 2021;19(8):1896 View
  30. Malik P, Temrikar Z, Chelle P, Edginton A, Meibohm B. Pediatric Dose Selection for Therapeutic Proteins. The Journal of Clinical Pharmacology 2021;61(S1) View
  31. Megías-Vericat J, Bonanad S, Haya S, Cid A, Marqués M, Ferrada A, Monte-Boquet E, Pérez-Alenda S, Bosch P, Querol-Giner F, Poveda J. Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients. Thrombosis Research 2021;205:99 View
  32. Bukkems L, Versloot O, Cnossen M, Jönsson S, Karlsson M, Mathôt R, Fischer K. Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A. Thrombosis and Haemostasis 2023;123(03):317 View
  33. Singkham N, Punyawudho B, Yu M, Cheng S, Chen S, Chang H, Chen C, Hsiao C, Hou J, Fang Y, Wang H, Lin J, Yu L, Chen Y. Influence of blood group and von Willebrand factor on population pharmacokinetics and dose individualization of recombinant factor VIII in Taiwanese patients with haemophilia A. Haemophilia 2022;28(2):230 View
  34. Versloot O, Iserman E, Chelle P, Germini F, Edginton A, Schutgens R, Iorio A, Fischer K. Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia. HemaSphere 2022;6(4):e694 View
  35. Desai D, Dherai A, Strik A, Mould D. Personalized Dosing of Infliximab in Patients With Inflammatory Bowel Disease Using a Bayesian Approach: A Next Step in Therapeutic Drug Monitoring. The Journal of Clinical Pharmacology 2023;63(4):480 View
  36. Megías-Vericat J, Bonanad Boix S, Berrueco Moreno R, Mingot-Castellano M, Rodríguez López M, Canaro Hirnyk M, Mateo Arranz J, Calvo Villas J, Haya Guaita S, Mesegué Medà M, López Jaime F, Albo-López C, Palomero-Massanet A, Vilalta Seto N, Leciñena I, Haro A, Poveda Andrés J. Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products. Thrombosis Research 2022;216:35 View
  37. Goedhart T, Janssen A, Mathôt R, Cnossen M. The road to implementation of pharmacokinetic-guided dosing of factor replacement therapy in hemophilia and allied bleeding disorders. Identifying knowledge gaps by mapping barriers and facilitators. Blood Reviews 2023;61:101098 View
  38. Hajducek D, Primacakti F, Chozie N, Mir R, McEneny-King A, Iorio A, Edginton A. Derivation of a Pharmacokinetic Model to Include a Plasma-Derived, von Willebrand Factor-Containing Factor VIII (Koate®-DVI) Concentrate and its Low-Dose Use. Plasmatology 2021;15 View
  39. Chandran R, Tohit E, Stanslas J, Salim N, Mahmood T, Rajagopal M. Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment. Seminars in Thrombosis and Hemostasis 2024;50(05):695 View
  40. Zhen Y, Ai D, Huang K, Li G, Chen Z, Wu R. The influence of dead space in blood sampling needle on FVIII level and pharmacokinetic profiles in children with hemophilia. Hematology 2024;29(1) View
  41. Matino D, Germini F, Chan A, Decker K, Iserman E, Chelle P, Edginton A, Oladoyinbo O, Trinari E, Keepanasseril A, Iorio A. Canadian clinical experience on switching from standard half‐life recombinant factor VIII (rFVIII), octocog alfa, to extended half‐life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada. Haemophilia 2024;30(2):345 View
  42. Chelle P, Hajducek D, Thibaudeau K, Hobson N, Iorio A, Shapiro A, Edginton A. Development of a Plasminogen Population PK model supporting prophylactic replacement therapy for Plasminogen deficient patients within the WAPPS‐Hemo platform. Haemophilia 2024;30(4):988 View